

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Trademarks, 2900 Crystal Drive, Arlington, Virginia 22202-3513, on 7-6-98.



BOX 566/GM 1644

LUD 5253.5 DIV. - JEL/NDH

FELER & LYNCH

By *Tami Kortopout*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*disk
filed
w/paper*

Applicants : Thierry BOON-FALLEUR et al.
Serial No. : 08/819,669
Filed : March 17, 1997
For : TUMOR REJECTION ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGENS AND USES THEREOF
Art Unit : 1644
Examiner : T. Cunningham

*111D
5/11/98
8-8-98*

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

July 6, 1998
RECEIVED

15 1998

SUPPLEMENTAL RESPONSE

SIR:

Further to their amendment of June 9, 1998, applicants ask that this application be amended as follows:

IN THE SPECIFICATION

Please replace the paper copy of sequence information and computer readable form thereof with the attached materials.

REMARKS

At page 5, point 10 of the Office Action of March 17, 1998, the Examiner stated:

"If any originally disclosed MAGE-1 amino acid sequence has been modified or corrected the applicant is requested to notify the Examiner of the correction and date the correction was made."